Engstrm J, Bjurstrm R
Additionally, the study analyzed specific GLP-1 agonists and AUD medications individually, and the results for AUD medications were aggregated for comparison
In December 2024, the FDA's Pharmacy Compounding Advisory Committee declined to include it on the 503A bulk drug substances list, meaning compounding pharmacies in the United States cannot legally produce it for individual prescriptions
The phase 2 trial ran for 48 weeks total, and the weight loss curve had not fully plateaued by that point, suggesting continued benefits beyond the trial period
Researchers often study BPC 157 and TB 500 alongside growth hormone secretagogues such as CJC-1295 and Ipamorelin, growth hormone-releasing hormone analogues like Tesamorelin and Sermorelin, and IGF-1 pathway compounds like IGF-1 LR3 each offering complementary insights into anabolic, regenerative, and metabolic signaling
Adult Dehydration